Biogen Inc (NASDAQ:BIIB) Stake Boosted by Keybank National Association OH

Keybank National Association OH increased its stake in Biogen Inc (NASDAQ:BIIB) by 1.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,075 shares of the biotechnology company’s stock after purchasing an additional 223 shares during the quarter. Keybank National Association OH’s holdings in Biogen were worth $3,759,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of BIIB. AQR Capital Management LLC increased its stake in Biogen by 33.7% in the 1st quarter. AQR Capital Management LLC now owns 4,219,856 shares of the biotechnology company’s stock worth $991,793,000 after purchasing an additional 1,063,775 shares in the last quarter. Boston Partners boosted its position in Biogen by 424.3% during the 1st quarter. Boston Partners now owns 922,718 shares of the biotechnology company’s stock worth $218,113,000 after acquiring an additional 746,711 shares during the period. Parnassus Investments CA boosted its position in Biogen by 80.0% during the 1st quarter. Parnassus Investments CA now owns 630,000 shares of the biotechnology company’s stock worth $148,919,000 after acquiring an additional 280,000 shares during the period. SG Americas Securities LLC boosted its position in Biogen by 121.6% during the 1st quarter. SG Americas Securities LLC now owns 44,081 shares of the biotechnology company’s stock worth $10,420,000 after acquiring an additional 248,369 shares during the period. Finally, MERIAN GLOBAL INVESTORS UK Ltd boosted its position in Biogen by 57.7% during the 1st quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 667,753 shares of the biotechnology company’s stock worth $157,843,000 after acquiring an additional 244,326 shares during the period. 91.11% of the stock is currently owned by hedge funds and other institutional investors.

A number of brokerages have commented on BIIB. Wedbush began coverage on Biogen in a research report on Wednesday, May 22nd. They set a “neutral” rating and a $231.00 price objective for the company. Cowen restated a “buy” rating and set a $275.00 price objective on shares of Biogen in a research report on Tuesday, July 30th. Mizuho restated a “hold” rating on shares of Biogen in a research report on Thursday, July 25th. Piper Jaffray Companies restated a “hold” rating on shares of Biogen in a research report on Friday, July 26th. Finally, JPMorgan Chase & Co. restated a “hold” rating on shares of Biogen in a research report on Wednesday, April 24th. Four analysts have rated the stock with a sell rating, twenty-three have issued a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $269.74.



Shares of Biogen stock traded up $3.71 during trading on Friday, hitting $231.34. 12,823 shares of the stock traded hands, compared to its average volume of 1,350,923. The stock has a market cap of $43.02 billion, a P/E ratio of 8.75, a PEG ratio of 0.86 and a beta of 0.99. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.22 and a current ratio of 2.46. Biogen Inc has a twelve month low of $216.12 and a twelve month high of $358.41. The company has a fifty day moving average price of $235.30 and a two-hundred day moving average price of $255.18.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Tuesday, July 23rd. The biotechnology company reported $9.15 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $7.58 by $1.57. The business had revenue of $3.62 billion during the quarter, compared to analyst estimates of $3.48 billion. Biogen had a return on equity of 44.89% and a net margin of 37.62%. The firm’s revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the company earned $5.80 EPS. On average, equities research analysts expect that Biogen Inc will post 32.41 EPS for the current fiscal year.

Biogen Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis.

Further Reading: How is a price target determined?

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc (NASDAQ:BIIB).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.